Literature DB >> 35070405

Prognosis of rectal neuroendocrine tumors after endoscopic resection: a single-center retrospective study.

Yue Zheng1, Kehang Guo1,2, Ruijie Zeng1,3, Zhendao Chen4, Wanwei Liu1, Xiaoguang Zhang1, Weimin Liang1, Jianhua Liu5, Hao Chen1, Weihong Sha1.   

Abstract

BACKGROUND: The efficacy of endoscopic resection in patients with rectal neuroendocrine tumors (NETs) which are less than 20 mm in diameter remains unclear. This study aimed to investigate the efficacy and outcomes of different types of endoscopic resection in patients with NETs.
METHODS: We performed a retrospective analysis and follow-up on 98 patients who underwent endoscopic resection for rectal NETs between August 2010 and October 2019 at Guangdong Provincial People's Hospital, China. The lesions were preoperatively classified according to their endoscopic morphology and measured by endoscopic ultrasound. Patients were divided into modified endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) groups depending on the endoscopic treatment they received. The en bloc resection rate, histopathological complete resection rate, and the complication rate of the 2 groups were evaluated after the operation. The risk factors for incomplete resection were also analyzed.
RESULTS: The average diameter of the 98 NETs was 6.29±2.90 mm (range, 2-15 mm). The en bloc resection rate of the modified EMR and ESD treatment groups was 97.2% (35/36) and 100% (62/62), respectively. The histopathological complete resection rate was 86.1% (31/36) and 87.1% (54/62), respectively. No tumor recurrence or tumor-related death occurred. There were no statistically significant differences in the rate of histopathological complete resection, perforation, or delayed hemorrhage between the 2 groups (P>0.05). Multivariate analysis demonstrated that the depth of tumor invasion (P=0.007) and tumor diameter (P<0.001) were independent risk factors for histopathological complete resection.
CONCLUSIONS: Modified EMR and ESD are safe and effective endoscopic approaches for the resection of rectal NETs ≤15 mm in diameter. Endoscopic resection requires a comprehensive preoperative evaluation of risk factors including the depth of tumor invasion and tumor diameter. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Rectal neuroendocrine tumor; efficacy; endoscopic resection; safety

Year:  2021        PMID: 35070405      PMCID: PMC8748065          DOI: 10.21037/jgo-21-391

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  36 in total

1.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms.

Authors:  Martyn Caplin; Anders Sundin; Ola Nillson; Richard P Baum; Klaus J Klose; Fahrettin Kelestimur; Ursula Plöckinger; Mauro Papotti; Ramon Salazar; Andreas Pascher
Journal:  Neuroendocrinology       Date:  2012       Impact factor: 4.914

2.  Clinical characteristics, risk factors and outcomes of asymptomatic rectal neuroendocrine tumors.

Authors:  Sun-Hye Ko; Myong Ki Baeg; Seung Yeon Ko; Hee Sun Jung
Journal:  Surg Endosc       Date:  2017-01-11       Impact factor: 4.584

3.  Endoscopic resection yields reliable outcomes for small rectal neuroendocrine tumors.

Authors:  Joon Han Jeon; Dae Young Cheung; Seong Jin Lee; Hyun Jin Kim; Hye Kang Kim; Hyung Jun Cho; In Kyu Lee; Jin Il Kim; Soo-Heon Park; Jae Kwang Kim
Journal:  Dig Endosc       Date:  2014-01-22       Impact factor: 7.559

4.  Rectal carcinoid tumors--treatment and prognosis.

Authors:  K S Naunheim; J Zeitels; E L Kaplan; J Sugimoto; K L Shen; C H Lee; F H Straus
Journal:  Surgery       Date:  1983-10       Impact factor: 3.982

Review 5.  [Rectal neuroendocrine tumors: endoscopic therapy].

Authors:  J Eick; J Steinberg; C Schwertner; W Ring; H Scherübl
Journal:  Chirurg       Date:  2016-04       Impact factor: 0.955

6.  Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

Authors:  Louis de Mestier; Come Lepage; Eric Baudin; Romain Coriat; Frédéric Courbon; Anne Couvelard; Christine Do Cao; Eric Frampas; Sébastien Gaujoux; Rodica Gincul; Pierre Goudet; Catherine Lombard-Bohas; Gilles Poncet; Denis Smith; Philippe Ruszniewski; Thierry Lecomte; Olivier Bouché; Thomas Walter; Guillaume Cadiot
Journal:  Dig Liver Dis       Date:  2020-03-28       Impact factor: 4.088

7.  Is endoscopic ultrasonography essential for endoscopic resection of small rectal neuroendocrine tumors?

Authors:  Su Bum Park; Dong Jun Kim; Hyung Wook Kim; Cheol Woong Choi; Dae Hwan Kang; Su Jin Kim; Hyeong Seok Nam
Journal:  World J Gastroenterol       Date:  2017-03-21       Impact factor: 5.742

8.  The outcomes of modified endoscopic mucosal resection and endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors and the value of endoscopic morphology classification in endoscopic resection.

Authors:  Xiang-Yao Wang; Ning-Li Chai; En-Qiang Linghu; Shao-Tian Qiu; Long-Song Li; Jia-Le Zou; Jing-Yuan Xiang; Xing-Xing Li
Journal:  BMC Gastroenterol       Date:  2020-06-26       Impact factor: 3.067

9.  The 2019 WHO classification of tumours of the digestive system.

Authors:  Iris D Nagtegaal; Robert D Odze; David Klimstra; Valerie Paradis; Massimo Rugge; Peter Schirmacher; Kay M Washington; Fatima Carneiro; Ian A Cree
Journal:  Histopathology       Date:  2019-11-13       Impact factor: 5.087

10.  The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study.

Authors:  Hui-Jen Tsai; Chun-Chieh Wu; Chia-Rung Tsai; Sheng-Fung Lin; Li-Tzong Chen; Jeffrey S Chang
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

View more
  1 in total

Review 1.  Endoscopic treatment for rectal neuroendocrine tumor: which method is better?

Authors:  Seung Min Hong; Dong Hoon Baek
Journal:  Clin Endosc       Date:  2022-07-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.